Bullous Pemphigoid (BP180 and BP230) Antibodies, IgG by ELISA

Bullous Pemphigoid Antigens, IgG

See Note

CLINICAL INFORMATION
Eczematous patches and pruritus for 6 weeks, unresponsive to topical therapy.

Specimen Details
s22-1p0000531 - Serum; collected: ; Received: 

DIAGNOSTIC INTERPRETATION
Normal IgG Bullous Pemphigoid Antigens, BP180 and BP230, antibody levels by ELISAs
(See Results and Comments including further testing recommendations)

RESULTS
Enzyme-Linked Immunosorbent Assay (ELISA)

Bullous Pemphigoid (BP)180 and BP230 IgG Antibodies

IgG BP180 antibody level: 2 U/mL
Reference Range:
Normal (negative) = Less than 9 U/mL
Increased (H) (positive) = 9 U/mL and greater

IgG BP230 antibody level: 1 U/mL
Reference Range:
Normal (negative) = Less than 9 U/mL
Increased (H) (positive) = 9 U/mL and greater

H = high/positive
L = low/negative
* = Abnormal, C = Critical

Comments
Patients with pemphigoid may show reactivity to multiple basement membrane zone components other than the BP180 and BP230 epitopes displayed in the tested ELISAs; therefore, these normal results do not rule out a diagnosis of pemphigoid. These results also do not rule out treated or evolving pemphigoid or other
immunobullous diseases. Clinical correlation is needed including direct immunofluorescence findings on a biopsy specimen and treatment status.

Serum testing for IgG and IgA basement membrane zone antibodies or, more broadly, for IgG and IgA basement membrane zone and cell surface antibodies by indirect immunofluorescence and additional ELISAs can provide further immunopathological/diagnostic information. Correlation with additional testing is recommended and may be performed on this serum specimen by contacting ARUP Client Services at 1-800-242-2787, option 2, with add-on test request(s) for:

- Basement Membrane Zone (Epithelial) Antibodies, IgG by IIF (ARUP test number 0092056)
- Basement Membrane Zone (Epithelial) Antibodies, IgA by IIF (ARUP test number 0092057), and
- Collagen Type VII Antibody, IgG by ELISA (ARUP test number 2010905)

or

Basement membrane zone and cell surface antibody-associated diseases (pemphigoid and pemphigoid variants, epidermolysis bullosa acquisita, and linear IgA disease including linear IgA bullous dermatosis) with:

- Basement Membrane Zone Antibodies, IgG by IIF (ARUP test number 0090299),
- Desmoglein 1 and Desmoglein 3 (Pemphigus) Antibodies, IgG by ELISA (ARUP test number 0090649), and
- Collagen Type VII Antibody, IgG by ELISA (ARUP test number 2010905).

Detection, patterns, and levels of diagnostic antibodies may fluctuate with disease manifestations. Monitoring antibody profiles by indirect immunofluorescence as well as antibody levels by ELISAs may aid in assessing disease expression and activity.

-----------

General

Major molecular structures in the basement membrane zone to which IgG pemphigoid antibodies bind have been identified and termed "BP180" for a 180 kDa bullous pemphigoid antigen (also known as bullous pemphigoid antigen 2, BPAG2, or type XVII collagen, COL17) and "BP230" for a 230 kDa bullous pemphigoid antigen (also known as bullous pemphigoid antigen 1, BPAG1). BP180 is a transmembrane component of the basement membrane zone with collagen-like domains; the non-collagenous 16A (NC16A) antigenic domain of BP180 has been identified as a main antigenic target. BP230 is in the hemidesmosomal plaque of basal cells in the epidermis. Serum levels of IgG BP180 and IgG BP230 antibodies are determined by enzyme-linked immunosorbent assays (ELISA), and serum levels of IgG BP180 antibodies may correlate with disease activity in pemphigoid, diminishing with treatment response. Up to 7 percent of individuals who do not have pemphigoid, including patients with other immunobullous diseases, have increased levels of IgG BP180 and/or BP230 antibodies by ELISAs. Patients with pemphigoid may show reactivity to multiple basement membrane zone components in addition to or other than the BP180 and BP230 epitopes displayed in the tested ELISAs. Type VII collagen is a component of anchoring fibrils within epithelial basement membrane zone (skin and mucous membranes) and is an antigenic target of IgG autoantibodies in patients with epidermolysis bullosa acquisita and in a subset of patients with bullous lupus erythematosus.

H=High, L=Low, *=Abnormal, C=Critical

ARUP LABORATORIES | 800-522-2787 | aruplab.com
500 Chipeta Way, Salt Lake City, UT 84108-1221
Jonathan R. Genzen, MD, PhD, Laboratory Director

 Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2787 | aruplab.com
500 Chipeta Way, Salt Lake City, UT 84108-1221
Jonathan R. Genzen, MD, PhD, Laboratory Director

Patient: Patient, Example
ARUP Accession: 22-173-114016
Patient Identifiers: 0123456789ABC, 012345
Visit Number (FIN): 0123456789ABC
Page 2 of 3 | Printed: 11/22/2022 8:06:29 AM
Testing Methods
Enzyme-Linked Immunosorbent Assay (ELISA)

IgG BP180 and IgG BP230 serum antibody levels determined by U.S. Food and Drug Administration (FDA)-approved ELISAs (Mesacup, MBL BION). [Two ELISAs]

Electronically signed by MD, on at:

Medical Director: MD
CLIA Number:

EER Bullous Pemphigoid Antigens, IgG

See Note
Authorized individuals can access the ARUP Enhanced Report using the following link:

https:

<table>
<thead>
<tr>
<th>Procedure</th>
<th>Accession</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bullous Pemphigoid Antigens, IgG</td>
<td>22-173-114016</td>
</tr>
<tr>
<td>EER Bullous Pemphigoid Antigens, IgG</td>
<td>22-173-114016</td>
</tr>
</tbody>
</table>

END OF CHART

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2787 | aruplab.com
500 Chipeta Way, Salt Lake City, UT 84108-1221
Jonathan R. Genzen, MD, PhD, Laboratory Director

Patient: Patient, Example
ARUP Accession: 22-173-114016
Patient Identifiers: 01234567890ABCD, 012345
Visit Number (FIN): 01234567890ABCD
Page 3 of 3 | Printed: 11/22/2022 8:06:29 AM